Evercore ISI Reiterates In-Line Rating for Savara (NASDAQ:SVRA)

Savara (NASDAQ:SVRA)‘s stock had its “in-line” rating restated by stock analysts at Evercore ISI in a note issued to investors on Wednesday, MarketBeat reports. They currently have a $5.00 target price on the stock, down from their prior target price of $7.00. Evercore ISI’s price target points to a potential upside of 56.74% from the company’s previous close.

Several other brokerages also recently issued reports on SVRA. JMP Securities restated a “market outperform” rating and issued a $9.00 price objective on shares of Savara in a research note on Tuesday, October 1st. HC Wainwright restated a “buy” rating and issued a $10.00 price target on shares of Savara in a research report on Tuesday, October 8th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, Savara has a consensus rating of “Moderate Buy” and a consensus target price of $10.17.

Savara Stock Down 1.8 %

SVRA stock opened at $3.19 on Wednesday. The stock has a market capitalization of $525.08 million, a price-to-earnings ratio of -7.60 and a beta of 1.02. The company has a 50-day moving average of $3.93 and a two-hundred day moving average of $4.21. Savara has a 52-week low of $3.09 and a 52-week high of $5.70. The company has a debt-to-equity ratio of 0.26, a current ratio of 11.31 and a quick ratio of 11.31.

Savara (NASDAQ:SVRA) last announced its earnings results on Tuesday, November 12th. The company reported ($0.11) earnings per share for the quarter, meeting the consensus estimate of ($0.11). As a group, equities research analysts anticipate that Savara will post -0.44 EPS for the current year.

Institutional Investors Weigh In On Savara

A number of institutional investors have recently bought and sold shares of SVRA. BNP Paribas Financial Markets lifted its holdings in shares of Savara by 92.3% during the 1st quarter. BNP Paribas Financial Markets now owns 73,494 shares of the company’s stock worth $366,000 after acquiring an additional 35,269 shares during the period. Swiss National Bank bought a new position in Savara during the first quarter worth about $732,000. ProShare Advisors LLC boosted its holdings in Savara by 9.0% during the first quarter. ProShare Advisors LLC now owns 25,715 shares of the company’s stock valued at $128,000 after purchasing an additional 2,114 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Savara by 2.5% in the 1st quarter. Vanguard Group Inc. now owns 6,063,620 shares of the company’s stock valued at $30,197,000 after purchasing an additional 148,673 shares during the period. Finally, CANADA LIFE ASSURANCE Co acquired a new position in shares of Savara in the 1st quarter worth approximately $35,000. Institutional investors and hedge funds own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.